Document Detail

Inhaled budesonide for treatment of recurrent wheezing in early childhood.
MedLine Citation:
PMID:  1975851     Owner:  NLM     Status:  MEDLINE    
77 children, aged 11 to 36 months (mean 24) with moderately severe recurrent wheezing, were treated with budesonide pressurised aerosol 400 micrograms twice daily or placebo for 12 weeks in a double-blind, parallel-group trial. Aerosols were inhaled from a spacer with a facemask. Budesonide significantly improved symptom scores of wheezing, sleep disturbance, and patient happiness. The frequency of severe exacerbations that required a course of oral prednisolone was also significantly reduced. The treatment effect appeared to be fully established after 6-8 weeks and no side-effects could be ascribed to the active treatment. The findings indicate that young children below 3 years of age can inhale a pressurised aerosol from a spacer with a facemask. Use of topically active glucocorticosteroids with this simple device may reduce symptoms and distress in young children with moderately severe recurrent wheeze and dyspnoea, and possibly reduce their requirement for oral steroids.
H Bisgaard; S L Munck; J P Nielsen; W Petersen; S V Ohlsson
Publication Detail:
Type:  Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial    
Journal Detail:
Title:  Lancet     Volume:  336     ISSN:  0140-6736     ISO Abbreviation:  Lancet     Publication Date:  1990 Sep 
Date Detail:
Created Date:  1990-10-12     Completed Date:  1990-10-12     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  2985213R     Medline TA:  Lancet     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  649-51     Citation Subset:  AIM; IM    
Department of Paediatrics, University Hospital of Copenhagen, Denmark.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Administration, Inhalation
Administration, Oral
Child, Preschool
Double-Blind Method
Drug Administration Schedule
Drug Evaluation
Glucocorticoids / administration & dosage*,  therapeutic use
Multicenter Studies as Topic
Pregnenediones / administration & dosage*,  therapeutic use
Randomized Controlled Trials as Topic
Respiratory Sounds / drug effects*
Time Factors
Reg. No./Substance:
0/Aerosols; 0/Glucocorticoids; 0/Pregnenediones; 51333-22-3/Budesonide

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Detection of cytomegalovirus nucleic acid sequences in pancreas in type 2 diabetes.
Next Document:  Location of facioscapulohumeral muscular dystrophy gene on chromosome 4.